Early T-precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) is a rare and aggressive subtype of T-cell leukemia with poor prognosis and resistance to standard treatments. We report a 21-year-old male with ETP-ALL/LBL who, after an initial complete remission with the HOELZER protocol, experienced early relapse and was refractory to subsequent FLEND and BFM protocols. Following disease progression and complications, he was treated with a combination of daratumumab, venetoclax, azacitidine, and dexamethasone. This regimen achieved complete remission after one cycle. This case highlights the potential of this combination therapy as an effective treatment for refractory ETP-ALL/LBL, suggesting further research is warranted to validate its efficacy and safety.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00277-024-06118-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A complete response with daratumumab, venetoclax, azacitidine and dexamethasone in a heavily pre-treated, chemo-refractory early T-precursor acute lymphoblastic leukemia/lymphoma patient.
Ann Hematol
January 2025
Department of Hematology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.
Early T-precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) is a rare and aggressive subtype of T-cell leukemia with poor prognosis and resistance to standard treatments. We report a 21-year-old male with ETP-ALL/LBL who, after an initial complete remission with the HOELZER protocol, experienced early relapse and was refractory to subsequent FLEND and BFM protocols. Following disease progression and complications, he was treated with a combination of daratumumab, venetoclax, azacitidine, and dexamethasone.
View Article and Find Full Text PDFA rare case of CD38-negative abdominal multiple extramedullary plasmacytoma and literature review.
Leuk Res Rep
December 2024
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Abdominal multiple extramedullary plasmacytoma (EMP) is a rare disease. CD38-negative relapsed/refractory EMP after treatment with daratumumab has never been reported. In 2020, a patient with jaundice was diagnosed with plasmacytoma in another hospital, which progressed one year after receiving multiline therapy.
View Article and Find Full Text PDFThe clinical efficacy of a daratumumab-based regimen in relapsed/refractory acute leukemia: a single-center experience.
Ann Hematol
October 2024
Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China.
Relapsed/refractory acute leukemia (R/R-AL) is associated with a low remission rate, short survival rate, and poor prognosis. Treating R/R-AL remains challenging as there is no standardized effective regimen; hence, there is a need for efficient therapies. CD38 expression has been observed in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
View Article and Find Full Text PDFThree years follow-up of Venetoclax in advanced-stage, relapsed or refractory AL amyloidosis with cardiac involvement and t(11;14) with BCL2 expression.
Ann Hematol
October 2024
Department of Medical Oncology and Hematology, University and University Hospital of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
Further line treatment of patients with advanced stage AL amyloidosis with cardiac involvement is challenging. Venetoclax is a promising option, especially in t(11;14) and BCL2 expression.In our multicentre observational study, we report the 3-year follow-up of Venetoclax treatment in 9 patients with advanced, relapsed or refractory AL amyloidosis with t(11;14) and BCL-2 expression in > 50% of plasma cells.
View Article and Find Full Text PDFOutcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy.
Amyloid
September 2024
Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.
Article Synopsis
- Daratumumab treatment for light chain (AL) amyloidosis can lead to early refractoriness, leaving patients with fewer options if they relapse or respond poorly.
- This study assessed the effectiveness of venetoclax therapy in AL patients with t(11;14) who had previously failed daratumumab, involving 31 subjects.
- Results showed a 97% overall hematologic response to venetoclax, with strong organ responses in patients with cardiac (74%) and renal (46%) involvement, indicating promising potential for venetoclax as a salvage therapy after daratumumab failure.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!